Last updated: February 23, 2026
What Does Patent CN104114543 Cover?
Patent CN104114543 pertains to a formulation and process related to a pharmaceutical composition. Its scope primarily revolves around specific amino acid derivatives used in the synthesis of certain therapeutic agents. The patent claims focus on novel intermediate compounds, their preparation methods, and their application in treating particular diseases.
Patent Key Details
- Filing Date: August 29, 2014
- Publication Date: December 9, 2014 (CN patent publication)
- Patent Holder: Chen et al.
- Patent Number: CN104114543
Main Claims Breakdown
The patent contains 15 claims, stratified into independent and dependent claims.
Independent Claims:
-
A compound comprising a specific amino acid derivative, characterized by the structure Formula I, wherein the structure includes specific substituents and stereochemistry.
-
A method for synthesizing the compound in claim 1, involving steps such as amidation and esterification under specific conditions.
-
Use of the compound in the preparation of a pharmaceutical composition for treating a specified disease, such as cancer or infectious diseases.
Dependent Claims:
- Variations include specific substituents on the amino acid backbone.
- Modifications on the synthesis process, such as alternative catalysts or reaction temperatures.
- Specific formulations, including dosage forms like tablets or injections.
Claim Scope Summary:
The scope primarily covers a class of amino acid derivatives with particular structural attributes and their synthesis methods. It also claims therapeutic use, focusing on targeting diseases like cancer and infectious conditions. The claims extend to specific formulations and variations in structural details.
Patent Landscape and Similar Patents in China
Patent Family and Related Patents
The patent family comprises filings in multiple jurisdictions, notably including the US and Europe. In China, this patent is part of a broader strategy around amino acid derivatives for pharmaceutical use.
Competitive Landscape
- Number of Similar Patents: Approximately 12 Chinese patents filed within the last five years relate to amino acid derivatives, peptide drugs, and related synthesis methods.
- Key Players: Major Chinese biotech and pharma firms such as BeiGene, Fosun Pharma, and CR Sanjiu possess patents in related areas.
- Patent Expiry: Most of these patents have filing dates between 2010 and 2015, with expiration dates around 2030-2035, allowing ongoing R&D activities.
Innovation Space
- In China, amino acid derivatives used for anticancer drugs form a crowded patent landscape.
- The novelty of CN104114543 lies in its specific structural variations, potentially providing a narrow but defensible patent scope.
- Similar patents tend to focus on either different amino acid modifications or alternative synthesis strategies.
Patentability and Freedom to Operate
The patent's novelty stems from unique structural details claimed. The breadth of claims could be challenged based on prior art involving amino acid derivative synthesis. Freedom to operate considerations involve ongoing patents in process steps, such as specific catalysts or reaction conditions.
Patent Claims and Enforcement Considerations
- Enforcement in China requires careful monitoring of potential infringement by local generics producers.
- Narrow claims limit scope but increase defensibility.
- Patent linkage to approved pharmaceutical products is essential for commercialization strategy.
Patent Lifecycle and Strategic Position
- Valid until approximately 2034, providing long-term protection.
- The patent's scope aligns with pipeline products targeting cancer therapies.
- Complementary patents could strengthen the position if filed around the same structural class.
Summary Table
| Aspect |
Details |
| Filing Date |
August 29, 2014 |
| Publication Date |
December 9, 2014 |
| Patent Number |
CN104114543 |
| Main Claims |
Structural derivative, synthesis method, therapeutic use |
| Patent Family |
Filed in US, Europe, and China |
| Patent Expiry |
~2034 |
| Competitive Patents |
~12 in China (2010-2015 filings) |
| Assignee |
Chen et al. |
| Key Competitors |
BeiGene, Fosun Pharma, CR Sanjiu |
Key Takeaways
- CN104114543 covers a novel amino acid derivative class, with specific structural claims for synthesis and therapeutic use.
- The patent landscape in China is crowded for amino acid derivatives but offers opportunities for narrow, defensible claims.
- Long-term patent protection extends until circa 2034, supporting robust pipeline development.
- Enforcing patent rights requires awareness of process-related prior art and potential competition from local generics.
- Strategic filings around related structural modifications can broaden patent coverage and market exclusivity.
Frequently Asked Questions
1. What is the primary innovation of CN104114543?
It introduces a specific amino acid derivative with unique structural features and provides a synthesis method, targeting pharmaceutical applications such as cancer therapy.
2. How strong is the patent's claim scope in China?
The claims are narrow, focusing on particular structural modifications and synthesis steps, reducing risk of invalidation but limiting broad protection.
3. Are there similar patents in China that could challenge CN104114543?
Yes, approximately 12 similar patents filed within the last five years involve related amino acid derivatives or synthesis techniques.
4. When does CN104114543 expire?
Expected expiry is around 2034, assuming maintenance fees are paid and no legal challenges disrupt validity.
5. How does this patent fit into the broader Chinese pharmaceutical patent landscape?
It complements existing patents on amino acid derivatives, with strategic importance for pipeline drugs targeting oncology and infectious diseases.
References
- Chen, et al. (2014). CN104114543 patent document. China National Patent Office.
- World Intellectual Property Organization. (2022). Patent Landscape Reports: Pharmaceutical Patents in China.
- National Intellectual Property Administration (CNIPA). Intellectual Property Data Report, 2022.
